LabCorp Announces Record 2017 Fourth Quarter and Full Year Results

Published on : 13 February 2018
  • Net Revenue: Q4 of $2.7 billion, up 13% over 2016; Full year of $10.2 billion, up 8% over 2016
  • Diluted EPS: Q4 of $6.81, up 289% over 2016; Full year of $12.21, up 74% over 2016
  • Adjusted EPS: Q4 of $2.45, up 14% over 2016; Full year of $9.60, up 9% over 2016
  • Free Cash Flow: Q4 of $468 million, up 25% from 2016; Full year of $1.1 billion, up 28% over 2016
  • 2018 Adjusted EPS guidance of $11.30 to $11.70
  • 2018 Free Cash Flow guidance of $1.1 billion to $1.2 billion

BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 6, 2018-- LabCorp® (or the Company) (NYSE: LH) today announced results for the fourth quarter and year ended December 31, 2017, and provided 2018 guidance.

"We achieved outstanding full year results, highlighted by revenue over $10 billion, adjusted EPS at the high end of our guidance range, and free cash flow in excess of $1.1 billion,” said David P. King, chairman and CEO. “Our performance in the quarter demonstrated our multi-faceted growth platform, as our Diagnostics and Drug Development businesses each delivered excellent performance through a combination of strategic acquisitions, organic initiatives, and margin improvement. We are well positioned for another year of strong performance in 2018 driven by momentum in our businesses, expansion of our capabilities and talent base, broadened geographic presence, and delivery of innovative solutions that only LabCorp can offer.”

The full release is available at the website of LabCorp.